Real-World French Study Evaluates First-Line Olaparib Combination in

A nationwide French “real-world” descriptive study has evaluated first-line olaparib combined with abiraterone and prednisone or prednisolone for adult men with metastatic castration-resistant prostate cancer. The analysis, published in Drugs – Real World Outcomes, covered 154 patients enrolled in France’s Early Access program between March 30, 2023, and September 25, 2024, with the dataset frozen on October 25, 2024. Investigators tracked treatment initiation patterns, comorbidities, prior therapies, and adverse events in routine oncology practice across metropolitan France. The study reported that real-world use matched safety parameters seen in controlled trials and did not change the established benefit–risk profile following European regulatory authorization. The paper also reviews epidemiology, treatment sequencing challenges, and the biological rationale for combining DNA-repair inhibition with androgen signaling blockade.